Research

The FDA has approved Chiesi's Filsuvez for partial thickness wounds associated with dystrophic (DEB) and junctional epidermolysis bullosa (JEB) in patients 6 months and older. This follows approval of the treatment by the European Commission in June 2022, as well as NICE's recommendation for use...

Data on the use of rigosertib in patients with RDEB-associated squamous cell carcinoma was presented at the European Academy of Dermatology and Venerology (EADV) Congress last week....

The National Institute for Health and Care Excellence (NICE) have recommended Filsuvez for the treatment of open wounds in junctional and dystrophic epidermolysis bullosa in the UK....

The FDA has approved the use of Krystal Biotech's B-VEC (Vyjuvek) in patients with dystrophic epidermolysis bullosa (DEB), both recessive and dominant, aged 6 months or over....

The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorization approval for Amryt Pharma’s Filsuvez, a topical gel for the treatment of partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa (EB).  Marketing authorization approval is required before a medicine can...

InMed Pharmaceuticals has expanded its Phase II trial of INM-755, a cannabinol cream, to include adolescents. The trial is designed to enroll up to 20 patients with all four types of inherited EB - dystrophic EB, EB Simplex, Junctional EB and Kindler Syndrome - and will...

Last week, Krystal Biotech announced its submission of a Biologics License Application to the US Food and Drug Administration (FDA) seeking approval of B-VEC for the treatment of dystrophic epidermolysis bullosa (DEB). B-VEC is a non-invasive, topical gene therapy, applied to DEB wounds, providing the patient's...

Yesterday, the European Commission approved Amryt Pharma's Filsuvez®, a gel treatment for partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in patients 6 months and older. The approval was supported by data from the Phase III EASE trial, the largest ever global...

Researchers at the University of Bristol are investigating the design and development of artificial skin to benefit Epidermolysis Bullosa sufferers. Dr Naghavi Zadeh and colleagues are collaborating with Sharmila Collins, Founder and Trustee of Cure EB, to understand life with EB and care requirements. The project...